Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 511 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014', provides an overview of the Type 1 Diabetes (Juvenile Diabetes)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Type 1 Diabetes (Juvenile Diabetes) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
Introduction 7
Type 1 Diabetes (Juvenile Diabetes) Overview 8
Therapeutics Development 9
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies 11
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes 20
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance 22
Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies 26
Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes 38
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 40
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 135
Drug Profiles 147
Type 1 Diabetes (Juvenile Diabetes) - Recent Pipeline Updates 400
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 476
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 479
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 480
Appendix 489

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2014 30
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2014 31
Number of Products under Development by Companies, H2 2014 33
Number of Products under Development by Companies, H2 2014 (Contd..1) 34
Number of Products under Development by Companies, H2 2014 (Contd..2) 35
Number of Products under Development by Companies, H2 2014 (Contd..3) 36
Number of Products under Development by Companies, H2 2014 (Contd..4) 37
Number of Products under Development by Companies, H2 2014 (Contd..5) 38
Number of Products under Development by Companies, H2 2014 (Contd..6) 39
Number of Products under Development by Companies, H2 2014 (Contd..7) 40
Number of Products under Investigation by Universities/Institutes, H2 2014 42
Comparative Analysis by Late Stage Development, H2 2014 43
Comparative Analysis by Clinical Stage Development, H2 2014 44
Comparative Analysis by Early Stage Development, H2 2014 45
Comparative Analysis by Unknown Stage Development, H2 2014 46
Products under Development by Companies, H2 2014 47
Products under Development by Companies, H2 2014 (Contd..1) 48
Products under Development by Companies, H2 2014 (Contd..2) 49
Products under Development by Companies, H2 2014 (Contd..3) 50
Products under Development by Companies, H2 2014 (Contd..4) 51
Products under Development by Companies, H2 2014 (Contd..5) 52
Products under Development by Companies, H2 2014 (Contd..6) 53
Products under Development by Companies, H2 2014 (Contd..7) 54
Products under Development by Companies, H2 2014 (Contd..8) 55
Products under Development by Companies, H2 2014 (Contd..9) 56
Products under Development by Companies, H2 2014 (Contd..10) 57
Products under Development by Companies, H2 2014 (Contd..11) 58
Products under Investigation by Universities/Institutes, H2 2014 59
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 60
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by 4SC AG, H2 2014 61
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ActogeniX NV, H2 2014 62
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2014 63
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2014 64
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by American Gene Technologies International Inc., H2 2014 65
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2014 66
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2014 67
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2014 68
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2014 69
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca PLC, H2 2014 70
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2014 71
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bayhill Therapeutics, Inc., H2 2014 72
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2014 73
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2014 74
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biodel Inc., H2 2014 75
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2014 76
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2014 77
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2014 78
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 79
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cebix Incorporated, H2 2014 80
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cellectis S.A., H2 2014 81
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2014 82
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Coronado Biosciences, Inc., H2 2014 83
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cortendo AB, H2 2014 84
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by CTI BioPharma Corp., H2 2014 85
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 86
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Pharmaceuticals, H2 2014 87
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology Limited, H2 2014 88
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2014 89
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 90
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DoNatur GmbH, H2 2014 91
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2014 92
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2014 93
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics, Inc., H2 2014 94
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2014 95
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Exsulin Corporation, H2 2014 96
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Extrawell Pharmaceutical Holdings Limited, H2 2014 97
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Flamel Technologies S.A., H2 2014 98
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2014 99
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2014 100
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2014 101
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline plc, H2 2014 102
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2014 103
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Halozyme Therapeutics, Inc., H2 2014 104
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 105
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Immunocore Limited, H2 2014 106
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 107
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2014 108
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2014 109
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2014 110
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2014 111
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 112
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kineta, Inc., H2 2014 113
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 114
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 115
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 116
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2014 117
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2014 118
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune, LLC, H2 2014 119
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2014 120
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck KGaA, H2 2014 121
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mertiva AB, H2 2014 122
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2014 123
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 124
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NasVax Ltd., H2 2014 125
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NeoStem, Inc., H2 2014 126
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NGM Biopharmaceuticals, Inc., H2 2014 127
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2014 129
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2014 130
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 131
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Opexa Therapeutics, Inc., H2 2014 132
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2014 133
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis, Inc., H2 2014 134
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2014 135
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy, Inc., H2 2014 136
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2014 137
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2014 138
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H2 2014 139
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Progen Pharmaceuticals Limited, H2 2014 140
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Provid Pharmaceuticals, Inc., H2 2014 141
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2014 142
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2014 143
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RhinoCyte, Inc., H2 2014 144
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2014 145
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2014 146
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2014 147
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2014 148
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2014 149
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2014 150
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Uni-Bio Science Group Ltd., H2 2014 151
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2014 152
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by X-BODY BioSciences, Inc., H2 2014 153
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2014 154
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2014 155
Assessment by Monotherapy Products, H2 2014 156
Assessment by Combination Products, H2 2014 157
Number of Products by Stage and Target, H2 2014 159
Number of Products by Stage and Mechanism of Action, H2 2014 162
Number of Products by Stage and Route of Administration, H2 2014 165
Number of Products by Stage and Molecule Type, H2 2014 167
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Recent Pipeline Updates, H2 2014 421
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2014 497
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2014 500